← All Delcath Systems, INC filings

Delcath Systems, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
DCTH
Delcath Systems, INC
10-K: Delcath Systems Reports Strong Revenue Growth, Advances Liver Cancer Therapies
Delcath Systems, Inc. reported a significant increase in revenue for 2025, driven by the commercial expansion of HEPZATO KIT in the US and CHEMOSAT in Europe, alongside positive clinical trial results for combination therapies.
NASDAQ
DCTH
Delcath Systems, INC
10-K: Delcath Systems Reports Increased Revenue Following HEPZATO KIT Commercial Launch in 2024
Delcath Systems' 10-K filing reveals a significant revenue increase driven by the commercial launch of HEPZATO KIT and continued CHEMOSAT sales in Europe.
NASDAQ
DCTH
Delcath Systems, INC
10-K: Delcath Systems Outlines Share Structure and Regulatory Landscape in 10-K Filing
Delcath Systems' 10-K filing details its capital structure, including common and preferred stock, outstanding warrants and options, and provides an overview of its regulatory environment and business risks.